N Leung

Summary

Affiliation: The Chinese University of Hong Kong
Country: China

Publications

  1. ncbi request reprint Treatment of chronic hepatitis B: case selection and duration of therapy
    Nancy Leung
    Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Road, Shatin, Hong Kong
    J Gastroenterol Hepatol 17:409-14. 2002
  2. ncbi request reprint Nucleoside analogues in the treatment of chronic hepatitis B
    N Leung
    Department of Medicine, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
    J Gastroenterol Hepatol 15:E53-60. 2000
  3. ncbi request reprint Lamivudine for chronic hepatitis B
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital, The Chinese University of Hong Kong, Hong Kong SAR
    Expert Rev Anti Infect Ther 2:173-80. 2004
  4. ncbi request reprint Viral breakthrough during lamivudine therapy for chronic hepatitis B
    Nancy Leung
    Alice Ho Miu Ling Hospital, Chinese University of Hong Kong, Hong Kong, SAR
    Intervirology 46:344-9. 2003
  5. ncbi request reprint Clinical experience with lamivudine
    Nancy Leung
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China
    Semin Liver Dis 22:15-21. 2002
  6. ncbi request reprint Management of viral hepatitis C
    Nancy W Y Leung
    Prince of Wales Hospital and Chinese University of Hong Kong, Hong Kong
    J Gastroenterol Hepatol 17:S146-54. 2002
  7. ncbi request reprint Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy
    N W Leung
    Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong
    Hepatology 33:1527-32. 2001
  8. ncbi request reprint Disease progression in Chinese chronic hepatitis C patients with persistently normal alanine aminotransaminase levels
    C K Hui
    Department of Medicine, Queen Mary Hospital, and Research Centre of Infection and Immunity, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
    Aliment Pharmacol Ther 25:1283-92. 2007
  9. ncbi request reprint 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection
    C K Hui
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    Aliment Pharmacol Ther 23:1171-8. 2006
  10. ncbi request reprint Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation
    C K Hui
    Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
    Am J Transplant 6:1600-8. 2006

Detail Information

Publications16

  1. ncbi request reprint Treatment of chronic hepatitis B: case selection and duration of therapy
    Nancy Leung
    Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Road, Shatin, Hong Kong
    J Gastroenterol Hepatol 17:409-14. 2002
    ..Preliminary data from IFN and lamivudine combination therapy show some promise, but there are conflicting results...
  2. ncbi request reprint Nucleoside analogues in the treatment of chronic hepatitis B
    N Leung
    Department of Medicine, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
    J Gastroenterol Hepatol 15:E53-60. 2000
    ..Combination of these nucleoside/nucleotide analogues with immune modulators may be the answer to eradicate the virus in short-term therapy and avoid the issue of drug resistance...
  3. ncbi request reprint Lamivudine for chronic hepatitis B
    Nancy Leung
    Alice Ho Miu Ling Nethersole Hospital, The Chinese University of Hong Kong, Hong Kong SAR
    Expert Rev Anti Infect Ther 2:173-80. 2004
    ....
  4. ncbi request reprint Viral breakthrough during lamivudine therapy for chronic hepatitis B
    Nancy Leung
    Alice Ho Miu Ling Hospital, Chinese University of Hong Kong, Hong Kong, SAR
    Intervirology 46:344-9. 2003
    ..Potent antiviral agents also lead to the decline of cccDNA in hepatocytes. Combination therapies may further improve efficacy and avoid viral breakthroughs...
  5. ncbi request reprint Clinical experience with lamivudine
    Nancy Leung
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China
    Semin Liver Dis 22:15-21. 2002
    ..This is accompanied by virological rebound and reversal of the initial therapeutic response, and sometimes by exacerbation of hepatitis. The need remains for effective, safe, and tolerable oral agents with durable activity against HBV...
  6. ncbi request reprint Management of viral hepatitis C
    Nancy W Y Leung
    Prince of Wales Hospital and Chinese University of Hong Kong, Hong Kong
    J Gastroenterol Hepatol 17:S146-54. 2002
    ..Therapy for children, the elderly, patients with comorbidity and extra-hepatic syndromes need to be addressed. Therapy is too expensive and not affordable to the majority of patients in developing countries...
  7. ncbi request reprint Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy
    N W Leung
    Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong
    Hepatology 33:1527-32. 2001
    ..Up to two thirds of patients with moderately elevated pretreatment ALT achieved HBeAg seroconversion after 3 years of therapy...
  8. ncbi request reprint Disease progression in Chinese chronic hepatitis C patients with persistently normal alanine aminotransaminase levels
    C K Hui
    Department of Medicine, Queen Mary Hospital, and Research Centre of Infection and Immunity, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
    Aliment Pharmacol Ther 25:1283-92. 2007
    ..However, it is uncertain which group of patients is at risk of disease progression...
  9. ncbi request reprint 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection
    C K Hui
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    Aliment Pharmacol Ther 23:1171-8. 2006
    ..Although 48-week therapy with pegylated-interferons has been shown to be effective for the treatment of chronic hepatitis B virus infection, the efficacy of a shorter duration of therapy with pegylated interferons is unknown...
  10. ncbi request reprint Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation
    C K Hui
    Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
    Am J Transplant 6:1600-8. 2006
    ..97). In conclusion, occult hepatitis B virus co-infection in patients with recurrent chronic hepatitis C infection was not associated with accelerated fibrosis progression or severe fibrosis after liver transplantation...
  11. ncbi request reprint How should we manage patients with non-alcoholic fatty liver disease in 2007?
    Henry L Y Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China
    J Gastroenterol Hepatol 22:801-8. 2007
    ..Lifestyle changes are the first line and mainstay of management...
  12. ncbi request reprint Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy
    Winnie Yeo
    Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China
    Hepatology 45:1382-9. 2007
    ..0217; hazard ratio = 1.650; 95% CI 1.076-2.531) affected survival significantly. Exploratory analysis revealed that high levels of pretreatment HBV DNA had a significantly higher incidence of severe hepatitis during chemotherapy...
  13. ncbi request reprint Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy
    Joseph J Y Sung
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
    Gastroenterology 128:1890-7. 2005
    ..This study aimed to determine whether intrahepatic hepatitis B virus (HBV) covalently closed circular (ccc) DNA and total HBV DNA levels at the end of therapy would predict sustained response to therapy...
  14. doi request reprint Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab
    Winnie Yeo
    Department of Clinical Oncology, Stanley Ho Centre for Emerging Infectious Diseases, School of Public Health, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China
    J Clin Oncol 27:605-11. 2009
    ....
  15. pmc Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy
    C K Hui
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Rd, Hong Kong SAR, China
    Gut 54:1597-603. 2005
    ..The hepatic outcome of hepatitis B surface antigen (HBsAg) positive patients undergoing chemotherapy after withdrawal of pre-emptive lamivudine is unknown...
  16. ncbi request reprint Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
    Ching Lung Lai
    University Department of Medicine, Queen Mary Hospital, Hong Kong, People s Republic of China
    Clin Infect Dis 36:687-96. 2003
    ..Patients with YMDD variants losing clinical response with a significant increase in the HBV DNA and ALT levels may require additional therapy...